Evidence for Efficacy of Antidepressants for Pain Is Limited
In 11 comparisons, antidepressants were efficacious, but they were inefficacious or evidence was inconclusive for 31 comparisons
Diagnosis & Disease Information
January 2023 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Beta Blocker Use Tied to Reductions in Violence
Seena Fazel of the University of Oxford, UK, and colleagues at the Karolinska Institute in Sweden compared the medicated and non-medicated periods of over 1.4 million beta blocker users.
Sleep Medication Used by 8.4% of Adults in 2020
8.4 percent of adults took sleep meds every day or most days in last 30 days; women were more likely to take sleep meds than men
Gepirone Under Review for Major Depressive Disorder
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
ACP Updates Clinical Guidelines for Major Depressive Disorder Treatment
The updated recommendations include both nonpharmacologic and pharmacologic interventions for adults in the acute phase of MDD.
Frequent Green Space Visits Linked to Lower Use of Certain Meds
Lower use of psychotropic, antihypertensive, and asthma medications observed; association attenuated by body mass index
Rykindo Approved for Schizophrenia, Bipolar Disorder
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Antipsychotics Increasingly Being Prescribed to Children
Period prevalence of all antipsychotic prescriptions increased 3.3 percent per year from 2000 to 2019
December 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
